Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Non-valvular Atrial Fibrillation (NVAF) Patients with Diabetes in a US Population

被引：0
|
作者：
Jeffrey S. Berger
Veronica Ashton
François Laliberté
Guillaume Germain
Brahim Bookhart
Dominique Lejeune
Julien Boudreau
Patrick Lefebvre
Matthew R. Weir
机构：
[1] New York University School of Medicine,
[2] Janssen Scientific Affairs,undefined
[3] LLC,undefined
[4] Groupe d’analyse,undefined
[5] Ltée,undefined
[6] University of Maryland School of Medicine,undefined
来源：
Advances in Therapy | 2023年 / 40卷
关键词：
Diabetes; Healthcare costs; Healthcare resource utilization; Non-valvular atrial fibrillation; Real-world; Rivaroxaban; Warfarin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1224 / 1241
页数：17
相关论文
共 50 条
  • [41] Risk Reduction of Stroke and Early Post-Stroke Mortality in Patients With Non-Valvular Atrial Fibrillation (NVAF): A Comparison of Rivaroxaban vs Warfarin
    Alberts, Mark
    Lin, Jennifer H.
    Chen Yen-Wen
    Bisht, Deepti
    Kogan, Emily
    Twyman, Kathryn
    Milentijevic, Dejan
    [J]. CIRCULATION, 2018, 138
  • [42] Population Pharmacokinetic Modeling for Edoxaban in Healthy Subjects and Patients with Non-valvular Atrial Fibrillation (NVAF)
    Yin, Ophelia Q. P.
    Miller, Raymond
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2013, 40 : S19 - S19
  • [43] Comparative Effectiveness of Dabigatran versus Warfarin in Patients With Non-Valvular Atrial Fibrillation
    Alonso, Alvaro
    Chen, Lin Y.
    MacLehose, Richard F.
    Lutsey, Pamela L.
    [J]. CIRCULATION, 2013, 128 (22)
  • [44] HEALTHCARE COSTS ASSOCIATED WITH NON-VALVULAR ATRIAL FIBRILLATION IN ITALY
    Cammarota, S.
    Citarella, A.
    Creazzola, S.
    De Marino, C.
    Izzo, P.
    La Bella, G.
    Piscitelli, R.
    Romagnuolo, F.
    Esposito, E.
    Guida, A.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A386 - A386
  • [45] Correlation between primary care physicians' attitudes and the utilization of warfarin in nursing home patients (NHP) with non-valvular atrial fibrillation (NVAF).
    Thompson, JR
    Hanley, JF
    Tung, N
    Ladwig, JW
    [J]. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2001, 49 (04) : S130 - S130
  • [46] WARFARIN DISCONTINUATION AND STROKE RISK AMONG PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
    Wang, J.
    Qiao, Y.
    Spivey, C. A.
    Liu, X.
    Phatak, H.
    Mardekian, J.
    Claflin, A. B.
    Kachroo, S.
    Abdulsatter, Y.
    Parker, R. B.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A8 - A9
  • [47] Persistence Among Patients with Non-Valvular Atrial Fibrillation Beginning Dabigatran or Warfarin
    Francis, Kevin M.
    Siu, Kimberly
    Yu, Chen
    Alvrtsyan, Hasmik
    Rao, Yajing
    Walker, David R.
    Sander, Stephen D.
    Zalesak, Martin
    Miyasato, Gavin
    Sanchez, Herman
    [J]. BLOOD, 2012, 120 (21)
  • [48] Cost-effectiveness of rivaroxaban versus warfarin in non-valvular atrial fibrillation patients with chronic kidney disease in China
    Liu, Lin
    Hong, Dongsheng
    Ma, Kuifen
    Lu, Xiaoyang
    [J]. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2021, 46 (03) : 658 - 668
  • [49] Resource utilization and treatment cost of stroke in patients with non-valvular atrial fibrillation (NVAF) using a retrospective cohort design in Germany
    Benhaddi, H.
    Lefevre, C.
    Ehreth, J.
    Amzal, B.
    Evans, D.
    Budd, D.
    [J]. CEREBROVASCULAR DISEASES, 2015, 39 : 162 - 162
  • [50] Real-world bleeding risk among non-valvular atrial fibrillation (NVAF) patients prescribed apixaban, dabigatran, rivaroxaban and warfarin: analysis of electronic health records
    Lin, I.
    Masseria, C.
    Mardekian, J.
    Frean, M.
    Phatak, H.
    Kamble, S.
    Abdulsattar, Y.
    Petkun, W.
    Menzin, J.
    Lip, G. Y. H.
    [J]. EUROPEAN HEART JOURNAL, 2015, 36 : 1084 - 1084
12345